Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

ClinicalTrials.gov ID: NCT00645073

Public ClinicalTrials.gov record NCT00645073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To compare the safety and efficacy of a ten-day course of therapy of cefdinir, 600 mg QD, to a ten-day course of therapy of levofloxacin, 500 mg QD, in the treatment of acute bacterial sinusitis.

Study identification

NCT ID: NCT00645073
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Abbott; Industry
Enrollment: 271 participants

Conditions and interventions

Conditions

Acute Bacterial Sinusitis

Interventions

cefdinir (Omnicef) Drug
levofloxacin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2003 (Type not available)
Primary completion: Mar 2004 (Actual)
Completion: Not listed
Last update posted: Mar 27, 2008

Started 2003

United States locations

U.S. sites: 23
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35211	—
Not listed	Birmingham	Alabama	35215	—
Not listed	Columbiana	Alabama	35051	—
Not listed	Eclectic	Alabama	36024	—
Not listed	Tuscaloosa	Alabama	35406	—
Not listed	Mesa	Arizona	85201	—
Not listed	Fresno	California	93703	—
Not listed	Fresno	California	93710	—
Not listed	Murray	Kentucky	42071	—
Not listed	Portage	Michigan	49024	—
Not listed	Eugene	Oregon	97404	—
Not listed	Lake Oswego	Oregon	97035	—
Not listed	Orangeburg	South Carolina	29118	—
Not listed	Kingsport	Tennessee	37660	—
Not listed	Milan	Tennessee	38358	—
Not listed	Corsicana	Texas	75110	—
Not listed	San Antonio	Texas	78205	—
Not listed	Salt Lake City	Utah	84109	—
Not listed	Salt Lake City	Utah	84121	—
Not listed	West Jordan	Utah	84084	—
Not listed	West Jordan	Utah	84088	—
Not listed	Winchester	Virginia	22601	—
Not listed	Spokane	Washington	99204	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00645073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 27, 2008 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00645073 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →